Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
News
-
The people against Gilead. Activists protest at the Brazilian patent office, calling for Gilead’s last sofosbuvir patent application to be rejected
Activists gathered at the Brazilian Patent Office (INPI) in Rio de Janeiro this week, and Gilead’s office in São Paulo....
-
Overpatented, overpriced: How excessive pharmaceutical patenting is extending monopolies and driving up drug prices
This new report by our partner I-MAK analyzes the twelve best selling drugs in the United States and shows how...
-
Dear Viiv, we’ve fixed your AIDS 2018 ‘letter’.
We thought ViiV’s large, expensive advert outside AIDS 2018 in Amsterdam needed some re-working. Such a shame to spend all that...
-
Stockouts in Argentina threaten continuation of HIV treatments
One of the costly side-effects of Argentina’s economic crisis is the stockout of essential medicines, with HIV and Hepatitis C...
-
Connect with us at AIDS 2018 – & increase access to HIV treatment!
Are you going to be at the International AIDS Conference (AIDS2018) in Amsterdam, or following from afar? Here’s how to...
-
The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system
Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices, reports Tahir Amin...
-
IP-Watch Q&A with Carlos Correa: The myth of IP incentives for all nations
Dr Carlos Maria Correa, an Argentinian economist and lawyer, is globally renowned for his expertise on international trade, intellectual property,...
-
IP-Watch Q&A with Othoman Mellouk: The myth behind health and trade agreements
Othoman Mellouk is the Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC), and campaign...
-
What community activism can achieve – ITPC’s 2017 Annual Review
ITPC is proud to share its 2017 Annual Review, titled What Community Activism Can Achieve. The report highlights our successes, challenges, and...
-
When will ViiV, Clinton Health and partners officially repair the mistake on missing out 39 countries from the DTG pricing agreement?
It has been six months since we alerted the Clinton Health Access Initiative (CHAI) to a glaring omission in the...
-
MMA position on DTG after trials identify potential safety concerns for use at the time of conception
Doultegravir (DTG) is a highly effective, tolerable antiretroviral medicine with a high barrier to resistance; in 2015, WHO recommended it...
-
Five years after the Indian Supreme Court’s Novartis verdict
Five years after this landmark decision, the impact is being felt around the world. India’s decision is frequently held up...